GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug. The latest readout from the ...
Hosted on MSN2mon
GSK gets expanded EU approval for Jemperli in endometrial cancerGSK (NYSE:GSK) has received expanded approval from the European Commission for its drug Jemperli, also known as dostarlimab, in the treatment of endometrial cancer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback